PDS Biotechnology Corporation

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PDS Biotechnology advances oncology pipeline with promising trial results

PDS Biotechnology's strategic focus on oncology pipeline advancement, strong interim trial results, and financial stability position the company for continued growth and clinical success.
While facing financial challenges and operational complexities, the company's proactive approach to trial designs, regulatory engagements, and commercialization strategies offer promising opportunities for future development.
Overall, PDS Biotechnology's performance in 2022 reflects a balance of achievements, challenges, and opportunities, underscoring a commitment to innovation and clinical progress in the oncology space.

PDS Biotechnology reports Q1 loss, progresses promising cancer therapies

PDS Biotechnology's Q1 performance reflects ongoing investment in clinical development.
Strengths lie in innovative therapies, upcoming Phase 3 trial, and manufacturing progress.
Challenges include financial losses, competition, and meeting trial milestones.
Opportunities exist in clinical advancements, partnerships, market demand, and investor confidence.

PDS Biotechnologies reports Q2 loss, progresses in clinical trials

PDS Biotechnologies faces increased expenses but maintains strong funding for future operations.
Progress in clinical programs and upcoming milestones provide growth opportunities.
Challenges include trial requirements and enrollment timelines, but company is managing well.

PDS Biotechnology reports promising cancer therapy results amidst financial challenges

PDS Biotechnology demonstrates clinical success with PDS0101 and PDS01ADC, while facing financial pressures and operational challenges.
Strategic strengths in oncology programs and proactive clinical development position the company for growth and potential partnerships.
Opportunities lie in diversification with PDS0202, expanding the pipeline, and leveraging positive data from upcoming investigator-initiated trials.
Navigating financial challenges, operational complexities, and maximizing therapeutic potential will be key for PDS Biotechnology's future success.

PDS Biotechnology reports Q4 loss, focuses on innovative cancer trials

PDS Biotechnology's Q4 2023 Earnings Call highlighted financial performance, strategic focus on innovative clinical trials, and promising data-driven decisions.
The company's strengths lie in its collaborations with the National Cancer Institute, advancements in Phase II programs, and a healthy cash balance supporting future funding.
Challenges include managing rising operating expenses, delivering on trial outcomes, and navigating market competition, while opportunities exist in establishing leadership in cancer therapies and attracting investors.
Overall, PDS Biotechnology's emphasis on data-driven strategies, strong financial position, and commitment to advancing cancer treatments position it for potential growth and success in the biopharmaceutical industry.

PDS Biotechnology reports Q3 loss, optimistic on Versamune HPV potential

PDS Biotechnology Corporation's Q3 2024 performance reflected increased R&D expenses and strategic trial design modifications.
Despite financial challenges and competitive pressures, the company remains optimistic about the potential of Versamune HPV.
Opportunities lie in advancing the VERSATILE-003 trial, leveraging positive feedback, and addressing unmet medical needs in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

FLORHAM PARK, N.J., Aug.  31, 2020  (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced its participation in Noble Capital Markets’ C-Suite Interview Series, presented by Channelchek. 

PDS Biotechnology Announces Participation in Noble Capital Markets C-Suite Interview Series

FLORHAM PARK, N.J., Aug.  13, 2020  (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of common stock (inclusive of the 900,000 shares that were sold pursuant to the underwriter’s full exercise of its option to purchase additional shares of common stock) at a public offering price of $2.75 per share. Certain insiders, including certain of the Company’s officers, purchased shares of PDS Biotechnology common stock in the offering.

PDS Biotechnology Corporation Announces Closing of Approx. $19 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares

PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q2 2020 Results - Earnings Call Transcript

FLORHAM PARK, N.J., Aug.  13, 2020  (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced its financial results for the second quarter ended June 30, 2020 and provided a business update.

PDS Biotechnology Reports Financial Results for the Second Quarter 2020 and Provides Business Update

FLORHAM PARK, N.J., Aug.  11, 2020  (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced the pricing of its previously announced underwritten public offering consisting of 6,000,000 shares of common stock at a public offering price of $2.75 per share. The gross proceeds to PDS Biotech from this offering are expected to be $16,500,000, before deducting underwriting discounts, commissions and other offering expenses. In addition, PDS Biotech has granted the underwriter a 30-day option to purchase up to 900,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on Thursday, August 13, 2020, subject to customary closing conditions.   

PDS Biotechnology Corporation Announces Pricing of $16.5 Million Public Offering of Common Stock

FLORHAM PARK, N.J., Aug.  10, 2020  (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by PDS Biotech. PDS Biotech intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares sold in the offering to cover over-allotments, if any.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 

PDS Biotechnology Corporation Announces Proposed Public Offering of Common Stock

FLORHAM PARK, N.J., July  30, 2020  (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that the Company will report financial results for the second quarter ended June 30, 2020 on Thursday, August 13, 2020, before the market opens. Following the release, Dr. Frank Bedu-Addo, Chief Executive Officer, Michael King, Interim Chief Financial Officer, and Dr. Lauren Wood, Chief Medical Officer will host a conference call to review the financial results and provide a business update.

PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2020 Financial Results

Versamune-CoV-2 (PDS0203) generated high levels of robust, long-lasting CD8 (killer) T-cell responses and potent neutralizing antibody responses within 14 days of vaccination Versamune-CoV-2 (PDS0203) generated high levels of robust, long-lasting CD8 (killer) T-cell responses and potent neutralizing antibody responses within 14 days of vaccination

PDS Biotech Announces Preclinical Data for PDS0203, a T-Cell Activating Recombinant Protein Vaccine Against COVID-19

PDS Biotech ramps up third infectious disease vaccine program, PDS0202 for influenza, following PDS0201 for tuberculosis and PDS0203 for COVID-19 PDS Biotech ramps up third infectious disease vaccine program, PDS0202 for influenza, following PDS0201 for tuberculosis and PDS0203 for COVID-19

PDS Biotech Collaborator Granted NIAID Award to Accelerate Development of Versamune®-Based Universal Influenza Vaccine

BioCryst Pharmaceuticals

ElectroCore Inc

Tetraphase Pharmaceuticals

Cardiff Oncology

As the virus spreads, if you’re looking to bet against the market or hedge, our deep learning algorithms paired with out Artificial Intelligence (“AI”) data has some Top Shorts named for you today.

Top Stocks To Short As Dow Surges From Boeing Gains

NCI-led Phase 2 clinical trial of this reported combination was initiated in June 2020 NCI-led Phase 2 clinical trial of this reported combination was initiated in June 2020

PDS Biotech Announces Publication of Preclinical Results of PDS0101 Combination by the National Cancer Institute in the Journal for ImmunoTherapy of Cancer

Brazilian government to provide initial funding support to progress development of Versamune®-based vaccine to prevent COVID-19 infection

PDS Biotechnology and Farmacore Biotechnology Announce Co-Development of PDS0204 COVID-19 Vaccine

FLORHAM PARK, N.J., June  15, 2020  (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that the first patient has been dosed in the National Cancer Institute’s (NCI) Phase 2 clinical study of PDS0101 in the treatment of advanced human papillomavirus (HPV) associated cancers. This clinical trial involves a combination of PDS0101 with two clinical development-stage immune-modulating agents, Bintrafusp alfa (M7824) and NHS-IL12.

PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 Led by the National Cancer Institute

Hoth Therapeutics

Wall Street sell-side analysts have issued buying recommendation ratings for shares of PDS Biotechnology Corp (NASDAQ:PDSB) and Hoth Therapeutics Inc (NASDAQ:HOTH), even though these stocks have fallen more than 59% over the past 52 weeks.

Wall Street Suggests Buying These 2 Falling Knives

FLORHAM PARK, N.J., June  04, 2020  (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced a Phase 2 clinical trial to evaluate its lead immunotherapy product, PDS0101, in combination with standard of care chemoradiotherapy for treatment of locally advanced cervical cancer.

PDS Biotech Announces Clinical Trial of Its Lead Immunotherapy Product, PDS0101, in Combination with Chemoradiotherapy in Advanced Cervical Cancer

PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q1 2020 Results - Earnings Call Transcript

FLORHAM PARK, N.J., May  13, 2020  (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced its financial results for the first quarter ended March 31, 2020 and provided a business update.

PDS Biotechnology Reports Financial Results for the First Quarter 2020 and Provides Business Update

NCI to study PDS0103, in addition to planned Phase 2 clinical evaluation of PDS0101 in combination with other therapeutic agents NCI to study PDS0103, in addition to planned Phase 2 clinical evaluation of PDS0101 in combination with other therapeutic agents

PDS Biotechnology Expands CRADA with the National Cancer Institute to Include Second Versamune®-Based Anti-Cancer Product

Expanded infectious disease program to address current and potential pandemics builds on existing tuberculosis collaboration

PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza; Delay of PDS0101 VERSATILE-002 trial

PRINCETON, N.J., April  09, 2020  (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-cell activating technology called Versamune® today announced that it has appointed Ilian Iliev, Ph.D. to its Board of Directors.

PDS Biotechnology Appoints Dr. Ilian Iliev to Board of Directors

PDS Biotechnology (PDSB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?

PRINCETON, N.J., March  23, 2020  (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Andrew Saik has resigned as the Company’s Chief Financial Officer (CFO) and a director of the board to pursue other professional opportunities, effective immediately.  Mr. Saik joined PDS Biotech following the merger with Edge Therapeutics in March 2019, where he was the CFO. The board of directors has initiated a search to identify a successor.

PDS Biotechnology Announces Resignation of Andrew Saik as CFO

PRINCETON, N.J., Feb.  27, 2020  (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced commencement of work under an Amended and Restated Material Transfer Agreement with Farmacore Biotechnology, experts in infectious diseases, to develop a novel tuberculosis (TB) immunotherapy based on Farmacore’s proprietary TB antigens and PDS Bio’s Versamune® platform technology.  The prior Material Transfer Agreement under which preliminary work commenced was Amended and Restated in December 2019 due to promising early pre-clinical results and to progress this next phase of development.

PDS Biotechnology Announces Commencement of Work Under a Pre-Clinical Collaboration with Farmacore Biotechnology for Tuberculosis

PRINCETON, N.J., Feb.  24, 2020  (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that it has appointed Kamil Ali-Jackson, Esq. to its Board of Directors. Ms. Ali-Jackson will be a member of the Board’s audit committee.

PDS Biotechnology Appoints Kamil Ali-Jackson, Esq. to Board of Directors

PRINCETON, N.J., Feb.  14, 2020  (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced the closing of its previously announced underwritten public offering of 9,230,770 shares of common stock at a public offering price of $1.30 per share.

News for PDS Biotechnology Corporation Stock (PDSB)